HEMATOL TRANSFUS CELL THER. 2025;xxx(xx):103733



HEMATOLOGY, TRANSFUSION AND CELL THERAPY

www.htct.com.br



ABEI

Review article

Q1 Blood storage effect of G6PD on RBC quality

- Q2 Andrew Evans Cobbinah ^(b) ^{a,*}, Benedict Sackey ^a, Mina Ofosu ^b, Herbert Ekoe Dankluvi ^{a,b}, Stephen Opoku ^a, Ampa Davis Frank ^c
- Q3 ^a Kwame Nkrumah University of Science and Technology, Kumasi, Ghana ^b Kumasi Technical University, Kumasi, Ghana ^c Blood Bank Department, Living Waters Hospital, Ejisu, Ghana

ARTICLE INFO

Article history: Received 22 August 2023 Accepted 27 September 2024 Available online xxx

Keywords: G6PD Oxidative stress Hemolysis Cellular membrane Homeostasis

ABSTRACT

Background: The most prevalent metabolic condition of red blood cells, glucose-6-phosphate dehydrogenase (G6PD) deficiency, affects around 35 million people globally. The highest prevalence is seen in tropical and subtropical areas of the eastern hemisphere, where it can affect up to 35 % of the population. G6PD deficiency, the most prevalent enzyme deficit, is not currently tested for in blood products. G6PD deficiency is a genetic factor that influences the quality of stored red blood cells impacting their ability to respond to oxidative stress. This hospital-based cross-sectional study aimed at assessing the prevalence of G6PD deficiency in donor blood and the impact of the enzyme deficiency on red cell indices during storage.

Method: A total of 57 blood bags were screened for G6PD deficiency. Red cell indices and blood film comments were investigated on Day 0, Day 7 and Day 14 of storage.

Results: Eight out of 57 (14%) had the G6PD full defect and 86% (49/57) had no defect. Over the course of 14 days storage, the hemoglobin and red blood cell count significantly decreased in G6PD-deficient blood units with a corresponding significant increase in mean corpuscular volume and red cell distribution width-standard deviation compared to baseline and normal G6PD activity. The blood film comment showed 85.7% normocytic normochromic, 2.0% microcytic hypochromic and 12.2% macrocytic hyperchromic from G6PDnon-deficient donors whereas G6PD-deficient donors had 75% normocytic normochromic with 12.5% microcytic hypochromic and 12.5% macrocytic hypochromic after 2 wk in storage.

Conclusion: Red blood cell count and hemoglobin reduce significantly in G6PD-deficient donor units during storage with an associated increased mean corpuscular volume indicating progressive loss of the cellular membrane homeostatic mechanism that could potentially result in further hemolysis during long term storage.

© 2025 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

* Corresponding author.

E-mail address: andrewcobbina80@gmail.com (A.E. Cobbinah). https://doi.org/10.1016/j.htct.2025.103733

^{2531-1379/© 2025} Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

2

ARTICLE IN PRESS

1 Introduction

One of the most common therapies for anemic hospitalized 2 patients is red blood cell (RBC) transfusions.¹ Patients with 3 sickle cell disease and thalassemia, in particular, require 4 chronic transfusions because of inherent RBC abnormalities 5 6 linked to increased hemolysis and inefficient erythropoiesis. Accelerated clearance of transfused RBCs results in several 7 side effects related to continuous RBC transfusion therapy, 8 including iron overload, alloimmunization, and perhaps 9 increased susceptibility to infection.² As a consequence, 10 numerous initiatives are made to supply the highest quality 11 RBC products. The Food and Drug Administration (FDA) estab-12 lishes acceptance criteria for RBC units at the end of their 13 maximum permitted storage period (42 days), which are pri-14 marily based on an average 24-hour post-transfusion recov-15 ery (PTR) rate of at least 75 % (i.e., 75 % of the transfused RBCs 16 should still be circulating 24 h after transfusion) and a <1 % 17 rate of in vitro hemolysis.3 Additionally, the proportion of 18 successful PTRs must have a one-sided, lower limit of the 19 95% confidence interval of at least 70%; in other words, there 20 21 can be no more than two unsuccessful PTRs of 75% in a cohort of 20 healthy volunteer blood donors. 22

PTRs are remarkably different between blood donors,⁴ with 23 these variations being distinct and recurrence-free for each 24 donor, indicating that some donors are strong iron storers 25 and others are poor iron storers.¹ Inter-donor metabolic het-26 27 erogeneity was discovered by in vitro tests of preserved RBCs; this heterogeneity can affect the metabolic age of stored RBC 28 units at least as much as their chronological age.⁵ Further-29 more, as RBC storage quality is heriTable,⁶ genetic factors 30 might be to blame for at least some of these variances. 31

The most prevalent human enzymopathy, glucose-6-32 phosphate dehydrogenase (G6PD) deficiency, is an X-linked 33 illness that affects around 400 million people worldwide.⁷ 34 The pentose phosphate pathway (PPP), which produces 35 reduced nicotinamide adenine dinucleotide phosphate 36 (NADPH), a cofactor that powers a number of antioxidant 37 38 pathways in RBCs, also depends on G6PD as its rate-limiting 39 enzyme.8 In fact, NADPH is necessary for glutathione reductase to recycle oxidized glutathione into its reduced form. The 40 thioredoxin reductase system, biliverdin reductase B, and the 41 ascorbate-tocopherol axis are just a few examples of the 42 numerous NADPH-dependent antioxidant enzymes it sup-43 ports.⁹ It also enhances catalase, glutathione peroxidase, per-44 oxiredoxins, glutaredoxins, and the thioredoxin reductase 45 system. The reduced ability of G6PD-deficient RBCs to pro-46 duce NADPH,¹ which can be brought on by drugs, infections, 47 and nutrition, makes them more vulnerable to oxidative 48 stress.¹⁰ 49

In refrigerated storage, oxidative stress indicators 50 increase,^{11,12} indicating that storage itself may contribute to 51 oxidative stress. PTR also increases noticeably in mice and 52 humans when RBCs are maintained under hypoxic condi-53 54 tions¹³ or in the presence of the antioxidant ascorbic acid,¹⁴ which reduces oxidative stress. RBCs do not appear to have 55 56 evolved to withstand the oxidative damage brought on by 57 cold storage however, they evolved defenses against oxidative stress as they age in vivo with some of these defenses 58

being triggered during typical blood bank storage. Studies 59 using stable isotope-labeled tracers, for instance, indicate 60 that storage-induced oxidation of Cys152 of the glycolytic 61 enzyme glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 62 results in a shift in the glucose metabolism toward the oxida- 63 tive phase of the PPP; this phenomenon is attenuated or exac-64 erbated by hypoxic or hyperoxic storage, respectively.¹⁵ 65 G6PD-deficiency reduces NADPH generation in RBCs, which 66 reduces their capacity to replenish the reduced form of gluta- 67 thione and prevent the buildup of peroxidation/inflammatory 68 products.¹⁶ G6PD is the most important enzyme in the oxida-69 tive phase of the PPP. In fact, blood units obtained from G6PD-70 deficient donors have altered glutathione homeostasis and 71 antioxidant defenses.¹⁷ 72

Method

Study design

73 74

This was a cross-sectional study to assess the prevalence of 75 G6PD deficiency among blood donors. It also has a comparative study design to assess the impact of G6PD deficiency on 77 stored RBCs as compared to non-G6PD-deficient stored RBCs. 78

Ethical considerations

Ethical clearance was obtained from the Committee on 80 Human Research Publications and Ethics (CHRPE) of the 81 School of Medicine and Dentistry, Kwame Nkrumah University of Science and Technology before the inception of the study. The management of Living Waters Hospital also gave 84 their approval for their facility to be used for this study. Moreover, consent was sought from blood donors who were 86 assured of the highly confidential nature of this study. 87

Sample collection

About 5 mL of blood was collected from each blood unit 89 donated in the blood bank from patients who had passed the 90 donor screening tests. These samples were used for the initial 91 analysis. Subsequently after 7 and 14 days, additional samples were collected from the same blood bags that had been 93 kept in a storage fridge. 94

The first set of samples were screened for G6PD deficiency 95 using the methemoglobin reductase technique. Thin films 96 were prepared, stained with Leishman stain and observed for 97 general film comment on the red cell morphology. Further 98 more, a complete blood count was performed on the samples 99 to determine red cell hematological indices. 100

Laboratory investigations

The procedure of the G6PD screening test

The methemoglobin technique of G6PD testing was done by 103 arranging three test tubes in a test tube rack with the labels 104 'Positive', 'Test' and 'Negative'. One mL each of a well-mixed 105 blood sample from a CPD-A1 anti-coagulant blood storage bag 106 was introduced into the three test tubes. Fifty μ L of a mixture 107 of sodium nitrite and glucose was dispensed into the tubes 108

) 1

79

88

101

102

<u>ARTICLE IN PRESS</u>

109 labelled 'positive' and 'test' and mixed and $50 \,\mu\text{L}$ of methy-110 lene blue was added to the tubes labelled 'test' and 'negative' 111 and mixed.

112 The test tube setups were then corked and incubated in a

113 water bath at 37 °C for 3 h. At the end of this time, the con-

114 tents of the tubes were diluted with physiological saline solu-

115 tion and observed against a white background. The result was

116 read as either full defect, partial defect or no defect.

117 Complete blood count

118 The blood sample collected from the blood bags into a plain 119 test tube was swirled to evenly distribute blood cells.

Following standard protocols, the complete blood count of all samples was analyzed using a MINDRY BC-3000Plus 3PARTS Automated Hematology Analyser from the Kumasi Technical University Clinic laboratory.

The parameters of interest of the complete blood count analysis were the hemoglobin (Hb) concentration, RBC count,

126 mean corpuscular volume (MCV), mean corpuscular Hb (MCH)

127 and mean corpuscular Hb concentration (MCHC) since the128 study focuses on RBC indices.

129 Blood film comment

130 Thin blood films of each sample were prepared and stained

131 with Leishman stain using the standard staining protocol, 132 with Leishman stain being flooded on the smear for 1-2 mins

and then diluted with buffered water at about twice the vol-

134 ume of the stain and allowed to stand for 15 mins. The slides

135 were then washed and blotted for observation.

The stained slides were observed by a student and the blood picture was confirmed by an independent experienced hematologist at the facility. The observed morphological characteristics of the cells were then used to categorize the cells.

141 Results

142 Socio-demographic characteristics of study participants

A total of 57 male blood donors were recruited for this study. 143 The mean age of the blood donors was 26.47 ± 3.723 years 144 (range: 19-38 years). The majority of the blood donors were in 145 the 21-25 (46.6 %) age group followed by 26-30 (36.2 %), whilst 146 the smallest age group was that of 36-40 (1.8%) years old. Of 147 the various blood groups, 45.6 % were of the O⁺ blood group, 148 149 followed by 24.6%, 17.5%, 5.3%, 3.5%, 1.8% and 1.8% of the 150 A⁺, B⁺, AB⁺, B⁻, A⁻ and O⁻ blood groups, respectively.

From the total of 57 blood donors recruited, 8 (14%) had the full defect for G6PD enzyme activity whilst 49 (86%) had no defect for G6PD activity. This gives a 14% (8/57) prevalence of G6PD deficiency among blood donors of this study (Table 1 and Figure 1).

156 General effect of storage on RBC indices of donor blood

157 At baseline, the mean Hb, RBC count, MCV, MCH, MCHC and 158 red cell distribution width-standard deviation (RDW-SD) of

159 the donor units were $13.00 \pm 1.99 \text{ g/dL}$, $4.55 \pm 0.62 \times 10^{12}$ /L,



Figure 1-Prevalence of G6PD status among blood donors.

Table 1 – Shows descriptive statistics of the blood donors in the study.				
Variable	Frequency	Percentage (%)		
Gender				
Male	57	100		
Female	0	0		
Total	57	100		
Age group-years				
16–20	2	3.5		
21–25	27	47.4		
26–30	21	36.8		
31–35	6	10.5		
36-40	1	1.8		
Total	57	100		
Blood group				
A-	1	1.8		
A+	14	24.6		
AB+	3	5.3		
B-	2	3.5		
B+	10	17.5		
O-	1	1.8		
O+	26	45.6		
Total	57	100		
G6PD Status				
No defect	49	86		
Full defect	8	14		
Total	57	100		

Comparing the hematological indices of the donor sam-162 ples from the baseline to Day 7 in storage, the mean Hb 163 decreased significantly (p-value = 0.023) from 13.00 ± 1.99 g/dL 164 to 12.78 ± 2.26 g/dL while the RDW increased significantly (p-165 value = 0.00) from 48.16 ± 3.5 fL to 50.24 ± 4.1 fL. However, the 166 RBC count (p-value = 0.368), MCV (p-value = 0.220), MCH (p-167 value = 0.336) and MCHC (p-value = 0.080) showed no signifi-168 cant changes (Table 2). 169

Comparing the data again from the baseline to day 14 in 170 storage, the mean Hb and MCHC decreased significantly from 171 13.00 ± 1.99 g/dL to 12.87 ± 2.57 g/dL (p-value = 0.009) and 172

MCHC (g/dL)

RDW-SD (fL)

ARTICLE IN PRESS

HEMATOL TRANSFUS CELL THER. 2025;xxx(xx):103733

0.08

0.00

Table 2 – Changes in red blood cell parameters of donor blood over a 7-day storage period.				
Variable	Baseline	7 days of storage	p-value	
Hb (g/dL) RBC (×10 ¹² /L)	$\begin{array}{c} 13.00 \pm 1.99 \\ 4.55 \pm 0.62 \end{array}$	$\begin{array}{c} 12.78 \pm 2.26 \\ 4.50 \pm 0.66 \end{array}$	0.023 0.368	
MCV (fL)	82.57 ± 9.71	83.43 ± 10.91	0.22	
MCH (pg)	$\textbf{27.48} \pm \textbf{4.36}$	$\textbf{27.21} \pm \textbf{4.41}$	0.336	

Hb: hemoglobin; RBC: Red blood cell; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW-SD: red cell distribution width-standard deviation.

 3260 ± 161

5024 + 41

173 33.10 ± 2.22 g/dL to 30.90 ± 2.08 g/dL (p-value = 0.002), respec-

174 tively, whereas the mean MCV and RDW increased signifi-

175 cantly from 82.57 \pm 9.71 fL to 87.96 \pm 14.32 fL (p-value = 0.001)

176 and 48.16 \pm 3.5 fL to 51.28 \pm 4.0 fL (p-value = 0.00), respectively.

177 However, the RBC count (p-value = 0.300) and MCH (p-

178 value = 0.284) showed no significant changes (Table 3).

 3310 ± 222

 48.16 ± 3.5

179 Impact of G6PD deficiency on RBC indices of stored donor blood180 units

181 The mean values of the RBC indices (Hb, MCV, MCH and 182 MCHC) of G6PD-deficient and G6PD-non-deficient blood dur-183 ing baseline analysis were slightly lower in full-defect blood 184 compared to non-defect blood. However, the mean RBC count 185 remained the same and the RDW was slightly higher in full-186 defect blood compared to non-defect blood.

G6PD-deficient samples showed significant decreases in Hb 187 concentration (p-value = 0.015) and RBC count (p-value = 0.025) 188 and a significant increase in RDW (p-value = 0.00) by the 7th 189 day of storage whilst donor blood with normal G6PD enzyme 190 activity maintained stable for Hb concentration (p-191 value = 0.161) and RBC count (p-value = 0.997) over this period. 192 Additionally, a significant reduction in MCHC (p-value = 0.053) 193 and an increase in RDW (p-value = 0.000) occurred in donor 194 blood with normal G6PD activity (Table 4). 195

196 Again, G6PD-deficient samples showed significant 197 decreases in Hb (p-value = 0.03) by the 14th day of storage 198 whilst donor blood with normal G6PD enzyme activity main-199 tained a stable Hb concentration over this period (p-200 value = 0.079). Additionally, a significant reduction in the RBC 201 count (p-value = 0.03) occurred in G6PD-deficient blood but

Table 4 – Comparison	of rec	d blood cell in	lices be	tween
G6PD-deficient $(n = 8)$	and	non-deficient	donor	blood
(n = 49) after 7 days stor	age.			

Variable	Baseline	7 days of storage	p-value
Hb (g/dL)			
G6PD defect	12.61 ± 1.64	11.92 ± 1.88	0.015
G6PD no defect	13.06 ± 2.04	12.92 ± 2.31	0.161
RBC (×10 ¹² /L)			
G6PD defect	4.56 ± 0.44	4.21 ± 0.44	0.025
G6PD no defect	4.55 ± 0.65	4.55 ± 0.68	0.997
MCV (fL)			
G6PD defect	$\textbf{79.23} \pm \textbf{12.85}$	$\textbf{79.80} \pm \textbf{15.13}$	0.761
G6PD no defect	83.12 ± 9.15	84.02 ± 10.14	0.238
МСН (рg)			
G6PD defect	25.65 ± 5.71	25.59 ± 5.48	0.923
G6PD no defect	$\textbf{27.78} \pm \textbf{4.10}$	27.48 ± 4.22	0.333
MCHC (g/dL)			
G6PD defect	31.88 ± 2.45	$\textbf{32.08} \pm \textbf{1.44}$	0.746
G6PD no defect	33.29 ± 2.14	$\textbf{32.69} \pm \textbf{1.64}$	0.053
RDW-SD (fL)			
G6PD defect	48.90 ± 50	50.99 ± 5.2	0.00
G6PD no defect	48.03 ± 3.3	50.12 ± 3.9	0.00

Hb: hemoglobin; RBC: Red blood cell; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW-SD: red cell distribution width-standard deviation.

not in donor blood with normal G6PD activity. There was a 202 general increase in MCV (p-value = 0.034) and RDW (p- 203 value = 0.05) which occurred in both G6PD-deficient and 204 G6PD-non-deficient blood by the 14th day of storage (Table 5). 205

Microscopic morphological assessment of G6PD-deficient and 206 non-deficient donor blood after storage 207

Analysis of blood film comments of 57 donor samples pre-208 sented with 89.8% of RBC samples with normocytic normo-209 chromic and 10.2% samples with microcytic hypochromic 210 blood pictures from G6PD-non-deficient donors whereas 211 G6PD-deficient donor samples showed 75% of samples with 212 normocytic normochromic blood picture, 12.5% with micro-213 cytic hypochromic picture and 12.5% with anisopoikilocytosis 214 during baseline analysis (Table 6). 215

After seven days of storage, 93.9% of samples from G6PD- 216 non-deficient donors presented with normocytic normochro- 217 mic and 6.1% with microcytic hypochromic blood pictures 218 whereas 75% of samples from G6PD-deficient donors were 219

Table 3 – Changes in red cell parameters of donor blood over a 14-day storage period.				
Variable	Baseline	7 days of storage	14 days of storage	p-value
Hb (g/dL) RBC (×10 ¹² /L) MCV (fL) MCH (pg) MCHC (g/dL) RDW-SD (fL)	$\begin{array}{c} 13.00 \pm 1.99 \\ 4.55 \pm 0.62 \\ 82.57 \pm 9.71 \\ 27.48 \pm 4.36 \\ 33.10 \pm 2.22 \\ 48.16 \pm 3.5 \end{array}$	$\begin{array}{c} 12.78 \pm 2.26 \\ 4.50 \pm 0.66 \\ 83.43 \pm 10.91 \\ 27.21 \pm 4.41 \\ 32.60 \pm 1.61 \\ 50.24 \pm 4.1 \end{array}$	$\begin{array}{c} 12.87 \pm 2.57 \\ 4.58 \pm 0.74 \\ 87.96 \pm 14.32 \\ 27.28 \pm 4.42 \\ 30.90 \pm 2.08 \\ 51.28 \pm 4.0 \end{array}$	0.009 0.300 0.001 0.284 0.002 0.000

Hb: hemoglobin; RBC: Red blood cell; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW-SD: red cell distribution width-standard deviation.

HEMATOL TRANSFUS CELL THER. 2025;xxx(xx):103733

Table 5 – Comparison of re	d blood cell indices betwe	en G6PD-deficient and non-de	ficient donor blood after 14 days	storage.
Variable	Baseline	7 days of storage	14 days of storage	p-value
Hb (g/dL)				
G6PD defect	12.61 ± 1.64	11.92 ± 1.88	11.8 ± 2.12	0.03
G6PD no defect	13.06 ± 2.04	12.92 ± 2.31	13.05 ± 2.62	0.079
RBC (×10 ¹² /L)				
G6PD defect	4.56 ± 0.44	4.21 ± 0.44	4.24 ± 0.46	0.03
G6PD no defect	4.55 ± 0.65	4.55 ± 0.68	4.63 ± 0.76	0.778
MCV (fL)				
G6PD defect	79.23 ± 12.85	$\textbf{79.80} \pm \textbf{15.13}$	83.40 ± 17.70	0.034
G6PD no defect	83.12 ± 9.15	84.02 ± 10.14	88.70 ± 13.77	0.00
MCH (pg)				
G6PD defect	25.65 ± 5.71	25.59 ± 5.48	25.71 ± 5.48	0.968
G6PD no defect	$\textbf{27.78} \pm \textbf{4.10}$	27.48 ± 4.22	27.53 ± 4.24	0.195
MCHC (g/dL)				
G6PD defect	31.88 ± 2.45	32.08 ± 1.44	30.68 ± 1.81	0.197
G6PD no defect	33.29 ± 2.14	32.69 ± 1.64	30.94 ± 2.13	0.00
RDW-SD (fL)				
G6PD defect	48.90 ± 5.0	50.99 ± 5.2	52.23 ± 5.5	0.05
G6PD no defect	48.03 ± 3.3	50.12 ± 3.9	51.12 ± 3.8	0.00

Hb: hemoglobin; RBC: Red blood cell; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW-SD: red cell distribution width-standard deviation.

Table 6 – Microscopic morphological variations between G6PD-deficient and G6PD-non-deficient donor units.			
Variable	Baseline	7 days of storage	14 days of storage
Film comment	n (%)	n (%)	n (%)
G6PD defect			
normocytic normochromic	6 (75)	6 (75)	6 (75)
microcytic hypochromic	1 (12.5)	1 (12.5)	0 (0)
macrocytic hypochromic	0 (0)	0 (0)	1 (12.5)
anisopoikilocytosis	1 (12.5)	1 (12.5)	1 (12.5)
Total	8 (100)	8 (100)	8 (100)
G6PD no defect			
normocytic normochromic	44 (89.8)	46 (93.9)	42 (85.7)
microcytic hypochromic	5 (10.2)	3 (6.1)	1 (2)
macrocytic hypochromic	0 (0)	0 (0)	6 (12.2)
anisopoikilocytosis	0 (0)	0 (0)	0 (0)
Total	49 (100)	49 (100)	49 (100)

normocytic normochromic, 12.5 % were microcytic hypochro-mic and 12.5 % had anisopoikilocytosis (Table 6).

Moreover, after 14 days of storage, the blood film comments of G6PD-non-deficient donors identified 85.7 % normocytic normochromic, 2 % microcytic hypochromic and 12.2 % macrocytic hypochromic samples and from G6PD-deficient donor blood 75 % samples were normocytic normochromic, 12.5 % were macrocytic hypochromic and 12.5 % had anisopoikilocytosis (Table 6 and Figure 2).

229 Discussion

This study was geared towards establishing the prevalence of
G6PD deficiency among blood donors at the Living waters
Hospital in the Ashanti region and any potential effect of
G6PD enzyme deficiency on RBC indices during storage in the
blood bank. The study recruited 57 blood donors all of whom
were male with the majority being between 21 and 25 (46.6 %)
and 26–30 (36.2 %) years old. The finding on males is that

men are the dominant gender in blood donations in line with 237 a study conducted at Sokoto in North Western Nigeria where 238 of a total of blood 14,965 donors from January 2010 to July 239 2013, 14,871 (99.4%) were males and only 94 (0.64%) were 240 female.¹⁸ Most studies in Africa reported a male dominance 241 in blood donation programs: 61 % in Togo,¹⁹ 71.2 % in Burkina 242 Faso²⁰ and 90 % in Ghana.²¹ In a recent survey in Central, 243 Western, and Eastern Franco-phone African regions, all seven 244 countries surveyed reported <30% females in their donor 245 populations.²² One contributing factor might be that women 246 do not meet donation cut-off values for hemoglobin due to 247 normal menses, menorrhagia, prenatal iron deficiency ane-248 mia and postnatal blood loss. From a cultural perspective 249 also, in various African countries it is more likely for males to 250 donate blood given long-standing beliefs that women are not 251 as physically strong as men.²³ In Western regions, such as 252 Europe, women were found to have higher rates of adverse 253 reactions, primarily vasovagal events, and were also not 254 as likely to meet hemoglobin cut-off requirements for 255 donation.²⁴ 256

6

ARTICLE IN PRESS

HEMATOL TRANSFUS CELL THER. 2025;**xxx(xx)**:103733



Sample 20: Normocytic normochromic on Day 7 and normocytic normochromic on Day 14



Sample 15: Macrocytic hypochromic on Day 14 and normocytic normochromic on Day 7



Sample 24: Anisopoikilocytosis on Day7 and anisopoikilocytosis on Day 14

Figure 2-Examples of the film comment results.

The age distribution observed in the present study was very similar to those reported by studies in Kenya, East Africa, where 59 % of voluntary donors were <25 years old,²⁵ in Burkina Faso, with a reported mean age of 28.9 ± 7.9 years,²⁶ and in Rwanda, where >75 % were <30 years old,²³ highlighting the fact that young people form the backbone of blood donation in these countries.

ABO distribution in this study showed that blood group O 264 265 Rh positive (45.6%) was the most predominant among the donors followed by A Rh positive (24.6%) and B Rh positive 266 (17.5%). The rarest blood groups were A Rh negative (1.8%) 267 and O Rh negative (1.8%). This finding is similar to a study 268 conducted in Cape Coast, Ghana by Patrick Adu et.al., where 269 O-positive was found predominant in 36.59 % and AB-positive 270 was the least common in 6.33% of the donations. Another 271 study, also in line with this result, reported that the O-posi-272 tive group was predominant and AB-positive was the least 273 common.²⁷ But other studies have reported different results 274 with A-positive being the predominant group followed by O-275 276 positive however AB-positive was still the least frequent.²

277 It was observed that, the prevalence of G6PD deficiency among blood donors was 14 % (8/57) which is higher than the 278 7.9% reported by Stephen et al. in Cameroon, Central 279 Africa.,²⁹ and slightly lower than the 19.5 % reported by Pat-280 rick et.al. at Berekum in the Brong Ahafo region of Ghana.³⁰ 281 However, Soheir et.al. reported a prevalence of G6PD defi-282 ciency of 4.3% in Egypt, East Africa.³¹ The differences in prev-283 alence between this study and other studies may be 284 attributed to the variations in population studied including 285 genetic factors, screening methods used and the sample size 286 of the population studied. 287

Storage of whole blood and components is necessary in order to provide support in many accident emergencies, and for obstetric bleeding and post-partum hemorrhage. Provision and storage of blood and blood components is therefore important in the hospital setting.³²

293 This study showed a general significant decrease in the Hb 294 concentration and MCHC levels during storage throughout 295 the study period whereas MCV levels had significantly increased by Day 14 suggesting that osmosis of fluid into the 296 RBC increases during storage as the RBC membrane is 297 impaired; this may ultimately lead to RBC hemolysis. This 298 observation confirms the report of Christian Eze et al. that, as 299 storage time increases, hemolysis increases in stored blood.33 300 In line with this assertion, L'Acqua et al. demonstrated that, 301 transfusion of RBCs stored for longer than 4 wk, considerably 302 increased plasma free Hb.³⁴ Additionally, a study by Houxiang 303 et al.,³⁵ also showed that free Hb and percentage of free to 304 total Hb in storage medium also significantly increased after 305 storage as adenosine triphosphate and 2,3-difosfoglicerato 306 levels were significantly decreased compared to fresh RBCs. 307

This study also showed that, despite both G6PD-deficient 308 and non-deficient blood donors fulfilled the minimum Hb 309 310 concentrations for blood donation, G6PD-deficient donors 311 had lower mean Hb concentrations compared to those of donors with normal G6PD enzyme activity. Additionally, over 312 the course of 14 days storage, the Hb concentration and RBC 313 count significantly decreased in G6PD-deficient blood units 314 with a corresponding significant increase in MCV compared 315 to the baseline which differed from insignificant variations 316

author., Hematology, Transfusion and Cell Therapy (2025), https://doi.org/10.1016/j.httt.2025.103733

observed in Hb, RBC and MCV of donor units with normal 317 G6PD activity. D'Almeida et al. reported decreases in RBC 318 deformability of 34 % following 4 wk of storage,³⁶ while Tsai et 319 al. also demonstrated that prolonged storage causes increases 320 in intracellular potassium and free Hb concentrations in the 321 suspending fluid plasma, resulting in a drop in pH leading to 322 decreased fraction of RBCs that survive after being returned 323 to circulation through transfusions.³⁷ 324

The significant drop in RBC count and concentration could 325 be due to increased hemolysis as demonstrated by Mattew et 326 al.,³⁸ the impact of G6PD status on RBC storage and transfusion outcomes. This could be the result of increased glycolysis, impaired glutathione homeostasis, and increased purine 329 oxidation. 330

Studies in which RBCs were exclusively stored in a manni-331 tol-containing additive solution (i.e., SAGM, AS-1, or AS-5) 332 showed a significant decrease in G6PD activity during stor-333 age.³⁹ In contrast, studies of RBCs in other storage solutions, 334 in general, did not suffer this effect.¹⁰ Consistent with the 335 finding of decreased G6PD activity in some studies, the trend 336 of declining PPP activity upon stimulation is seen during RBC storage.¹⁵ Therefore, these varied results may be explained by 338 differences in storage conditions or the methods used to 339 assess G6PD function. 340

Very few studies have been carried out on the effect of 341 G6PD deficiency on peripheral blood film comment. One study 342 conducted by Sutasir et al. on G6PD deficiency shows that 343 routine staining of peripheral smears reveals polychromasia, 344 representing increased RBC production. So-called bite cells 345 caused by the splenic removal of denatured Hb may be seen 346 as can Heinz bodies (denatured Hb) on the peripheral smear in cases of G6PD deficiency.⁴⁰ 348

Contrary to our findings, there were no significant presen-349 tations on peripheral blood film of G6PD-deficient donor blood 350 as compared to normal G6PD donor blood throughout the 351 study period. This difference in findings can be attributed to 352 the small sample size of the present study because of the 353 short period given for the study and the short duration of 354 storage of only 14 days. Significant changes were seen by 355 other researchers from 3 wk. 356

Limitations

Because this study was conducted in the era of the COVID-19358pandemic, the rates of blood donation at various health cen-359ters were drastically reduced hence the small sample size.360

Again because of limited resources, extension of unit monitoring beyond 14 days and inclusion of additional parameters such a cellular oxidative stress indices were not possible. 363

Recommendations

Based on the findings, the authors recommend;

The need for a multifacility study with a larger sample size 366 to assess a holistic information on the burden of G6PD deficiency, especially in sub-Saharan Africa. This will enhance 368 donor blood quality during transfusions. 369

357

364

365

A policy should be formulated for G6PD deficiency screening to be included in the screening list for blood donors. This should be observed in all facilities involved in blood donation.

373 Conclusion

The most prevalent enzyme deficiency worldwide is G6PD-374 375 deficiency. Overall, despite the strong recommendations of the World Health Organization, screening blood donors for 376 G6PD deficiency is not a common practice, and so blood banks 377 and transfusion services have G6PD-deficient RBCs in their 378 inventories. The RBC count and Hb concentration reduce sig-379 nificantly in G6PD-deficient donor blood units in storage with 380 an associated increase in MCV indicating progressive loss of 381 the cellular membrane homeostatic mechanism that could 382 potentially result in further hemolysis during long term stor-383 384 age

Transfusion of G6PD-deficient blood units may thus not yield optimum transfusion outcomes. This may show up in individuals with higher underlying oxidative stress, such as newborns, people with sickle cell disease, and those using oxidative drugs, as well as lower post-transfusion reactivity of stored G6PD-deficient RBCs and decreased transfusion efficacy in patients.

392 Declaration

I hereby declare that this submission is my own work towards
the BSc. Degree in Medical Laboratory Technology and that to
the best of my knowledge, it contains no material previously
published by another person nor material which has been
accepted for the award of any other degree of the university,
except for references to other people's work, which have been
duly acknowledged.

400 Ethics approval and consent to participate

Ethical clearance was obtained from the Committee on 401 Human Research Publications and Ethics (CHRPE) of School of 402 Medicine and Dentistry, Kwame Nkrumah University of Sci-403 ence and Technology before the inception of the study. Man-404 agement of Living Waters Hospital also gave approval for 405 their facility to be used for this study. Consent was sought 406 from blood donors who were assured of the highly confiden-407 tial nature of this study. 408

409 **Consent for publication**

410 Consent for publication was sought from the different411 authors involved in the development of this work.

412 Availability of data and material

413 Data of this research is available only on request since is a 414 clinical data.

Funding

415

418

The research work was financed solely by the corresponding 416 author. 417

Authors contribution

BS is the principal investigator and carried out the model 419 design and the computational framework. AEC designed the 420 model, the computational framework and the analysis of the 421 data and the writing of the article. SO was involved in reagent 422 preparation, laboratory investigations and data analysis. HD 423 helped in the reagent preparation and laboratory investigations. DFA helped in sample collection and storage monitoring. MO assisted in the manuscript development and editing. 426

Abbreviations

G6PD: Glucose 6-phosphate dehydrogenase, NADPH: Nicotin- 428 amide adenine dinucleotide phosphate, Hb: Hemoglobin, 429 MCV: Mean cell volume, MCH: Mean cell hemoglobin, RBC: 430 Red blood cell, MCHC: Mean cell hemoglobin concentration, 431 PPP: Pentose phosphate pathway 432

Conflicts of interest

Not applicable.

Acknowledgement

Authors acknowledge the key roles performed by the follow- 436 ing organizations; 437

• Living Waters Hospital for providing the needed facilities, 438

• Kwame Nkrumah University of Science and Technology 439 and 440

• Kumasi Technical University for their valuable contribu- 441 tions. 442

R E F E R E N C E S

- Francis RO, D'Alessandro A, Eisenberger A, Soffing M, Yeh R, 444 Coronel E, et al. Donor glucose-6-phosphate dehydrogenase 445 deficiency decreases blood quality for transfusion. J. Clin. 446 Invest. 2020;130(5):2270–85. 447
- Yoshida T, Prudent M, D'Alessandro A. Red blood cell storage 448 lesion: causes and potential clinical consequences. Blood 449 Transfusion. 2019;17(1):27. 450
- Koch CG, Duncan AI, Figueroa P, Dai L, Sessler DI, Frank SM, 451 et al. Real age: red blood cell aging during storage. Ann. 452 Thorac. Surg. 2019;107(3):973–80.
- Dumont LJ, AuBuchon JP, BEfST Collaborative. Evaluation of proposed FDA criteria for the evaluation of radiolabeled red cell recovery trials. Transfusion (Paris). 2008;48(6):1053–60.
- D'Alessandro A, Culp-Hill R, Reisz JA, Anderson M, Fu X, Nemkov T, et al. Heterogeneity of blood processing and storage additives in different centers impacts stored red blood cell

Please cite this article as: A.E. Cobbinah et al., Blood storage effect of G6PD on RBC qualityPlease provide official email id for the corresponding author., Hematology, Transfusion and Cell Therapy (2025), https://doi.org/10.1016/j.htct.2025.103733

427

433

434

435

443

HEMATOL TRANSFUS CELL THER. 2025;**xxx(xx)**:103733

- 460 metabolism as much as storage time: lessons from REDS-III—
 461 Omics. Transfusion (Paris). 2019;59(1):89–100.
- 462 6. Van't Erve TJ, Wagner BA, Martin SM, Knudson CM, Blendow463 ski R, Keaton M, et al. The heritability of hemolysis in stored
 464 human red blood cells. Transfusion (Paris). 2015;55(6):1178–85.
- 7. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The
 global prevalence of glucose-6-phosphate dehydrogenase
 deficiency: a systematic review and meta-analysis. Blood
 Cells, Molecul Dis. 2009;42(3):267–78.
- 469 8. Luzzatto L, Arese P. Favism and glucose-6-phosphate dehy 470 drogenase deficiency. New Engl J Med. 2018;378(1):60–71.
- 471 9. Van Zwieten R, Verhoeven AJ, Roos D. Inborn defects in the
 antioxidant systems of human red blood cells. Free Rad Biol
 473 Med. 2014;67:377–86.
- 474 10. Francis RO, Jhang JS, Pham HP, Hod EA, Zimring JC, Spitalnik
 475 SL. Glucose-6-phosphate dehydrogenase deficiency in trans476 fusion medicine: the unknown risks. Vox Sang. 2013;105
 477 (4):271–82.
- 478 11. Roback JD, Josephson CD, Waller EK, Newman JL, Karatela S,
 479 Uppal K, et al. Metabolomics of ADSOL (AS-1) red blood cell
 480 storage. Transfus Med Rev. 2014;28(2):41–55.
- 481 12. Gevi F, D'Alessandro A, Rinalducci S, Zolla L. Alterations of red
 482 blood cell metabolome during cold liquid storage of erythro483 cyte concentrates in CPD–SAGM. J Proteomics. 2012;76:168–80.
- 484 13. Dumont LJ, Yoshida T, AuBuchon JP. Anaerobic storage of red
 blood cells in a novel additive solution improves in vivo recovery. Transfusion (Paris). 2009;49(3):458–64.
- 14. Stowell SR, Smith NH, Zimring JC, Fu X, Palmer AF, Fontes J,
 et al. Addition of ascorbic acid solution to stored murine red
- blood cells increases posttransfusion recovery and decreases
 microparticles and alloimmunization. Transfusion (Paris).
 2013;53(10):2248–57.
- 492 15. Reisz JA, Wither MJ, Dzieciatkowska M, Nemkov T, Issaian A,
 493 Yoshida T, et al. Oxidative modifications of glyceraldehyde 3494 phosphate dehydrogenase regulate metabolic reprogramming
 495 of stored red blood cells. Blood. 2016;128(12):e32–42.
- 496 16. Tzounakas VL, Kriebardis AG, Georgatzakou HT, Foudoulaki497 Paparizos LE, Dzieciatkowska M, Wither MJ, et al. Data on how
 498 several physiological parameters of stored red blood cells are
 499 similar in glucose 6-phosphate dehydrogenase deficient and
 500 sufficient donors. Data Brief. 2016;8:618–27.
- Tzounakas VL, Kriebardis AG, Georgatzakou HT, Foudoulaki Paparizos LE, Dzieciatkowska M, Wither MJ, et al. Glucose 6 phosphate dehydrogenase deficient subjects may be better
 "storers" than donors of red blood cells. Free Radical Biol Med.
 2016;96:152–65.
- 18. Ol Erhabor, Zl Isaac, Abdulrahaman Y, Ndakotsu M, Ikhuenbor
 D, Aghedo F, et al. Female gender participation in the blood
 donation process in resource poor settings: case study of
 Sokoto in North Western Nigeria. J Blood Disord Transfus.
- 510 2013;5:176.
 511 19. Agbovi K, Kolou M, Fétéké L, Haudrechy D, North M, Ségbéna
 512 A. Knowledge, attitudes and practices about blood donation. A
 513 sociological study among the population of Lomé in Togo.
- 514 Transfusion Clin Et Biol. 2006;13(4):260–5.
 515 20. Nébié K, Olinger C, Kafando E, Dahourou H, Diallo S, Kientega
- 516 Y, et al. Lack of knowledge among blood donors in Burkina
 517 Faso (West Africa); potential obstacle to transfusion security.
 518 Transfusion Clin et Biol. 2007;14(5):446–52.
- 519 21. Allain JP, Sarkodie F, Boateng P, Asenso K, Kyeremateng E,
 520 Owusu-Ofori S. A pool of repeat blood donors can be generated
 521 with little expense to the blood center in sub-Saharan Africa.
- with little expense to the blood center in sub-SalTransfusion (Paris). 2008;48(4):735–41.
- 523 22. Tagny CT, Diarra A, Yahaya R, Hakizimana M, Nguessan A,524 Mbensa G, et al. Characteristics of blood donors and donated

blood in sub-Saharan Francophone Africa. Transfusion (Paris). 525 2009;49(8):1592–9. 526

- 23. Rushton DH, Dover R, Sainsbury AW, Norris MJ, Gilkes JJ, Ram-527 say ID. Why should women have lower reference limits for 528 haemoglobin and ferritin concentrations than men? BMJ. 529 2001;322(7298):1355–7. 530
- Bani M, Giussani B. Gender differences in giving blood: a 531 review of the literature. Blood Transfus. 2010;8(4):278. 532
- 25. Kimani D, Mwangi J, Mwangi M, Bunnell R, Kellogg T, Oluoch
 T, et al. Blood donors in Kenya: a comparison of voluntary and
 family replacement donors based on a population-based survey. Vox Sang. 2011;100(2):212–8.
 536
- Bartonjo G, Oundo J, Mwangi J. Prevalence and associated risk factors of transfusion transmissible infections among blood donors at Regional Blood Transfusion Center Nakuru and Tenwek Mission Hospital, Kenya. Pan African Med J. 2019;34(1).
- Hamed C, Bollahi M, Abdelhamid I, Med Mahmoud M, Ba B, 541 Ghaber S, et al. Frequencies and ethnic distribution of ABO and Rh (D) blood groups in Mauritania: results of first nationwide study. Int. J. Immunogenet. 2012;39(2):151–4. 544
- GÜNDEM NS, ATAŞ E. Distribution of ABO and Rh blood groups
 among patients admitted to a gynaecology, Obstetrics and Chil dren Hospital in Konya, Turkey. J Clin Diagn Res. 2019;13(3).
- Anstrom K.J., Noth I., Flaherty K.R., Edwards R.H., Albright J., 548 Baucom A. Maria Brooks5, Allan B. Clark6, Emily S. Clausen7, 549 Michael T. Durheim1, 8, Dong-Yun Kim9, Jerry Kirchner1 et al. 550 and for the CleanUP-IPF Study Team. 2020.
- Adu P, Kubi GA, Kumi A, Gbedoho RE, Kwakye FA, Sarpong E, 552 et al. Blood donors' Age, haemoglobin type, G6PD status, and Blood group impact storability of CPDA-1 banked whole Blood: 554 a repeated-measure cohort study in Cape Coast. Adv Hematol. 555 2020;2020:1–8. 556
- Elella SA, Tawfik M, Barseem N, Moustafa W. Prevalence of glucose-6-phosphate dehydrogenase deficiency in neonates in Egypt. Ann Saudi Med. 2017;37(5):362–5.
- Organization W.H. Guidance on ensuring a sufficient supply of safe blood and blood components during emergencies. 2023.
- 33. Christian SG, Eze EM, Nkom NE. Assessment of blood storage 562 effect using cpda-1 on packed cell volume, oxyhaemoglobin 563 and methaemoglobin in different abo/rhesus blood types. Int Blood Res Rev. 2019;9(4):1–15. 565
- L'Acqua C, Hod E. New perspectives on the thrombotic complications of haemolysis. Br. J. Haematol. 2015;168(2):175–85.
- Hu H, Xenocostas A, Chin-Yee N, Lu X, Chin-Yee I, Feng Q. Transfusion of fresh but not old stored blood reduces infarct size and improves cardiac function after acute myocardial infarction in anemic rats. Crit. Care Med. 2012;40(3):740–6.
- 36. d'Almeida M, Jagger J, Duggan M, White M, Ellis C, Chin-Yee I. 572
 A comparison of biochemical and functional alterations of rat 573
 and human erythrocytes stored in CPDA-1 for 29 days: impli-574
 cations for animal models of transfusion. Transfusion Med. 575
 2000;10(4):291–303. 576
- Tsai AG, Hofmann A, Cabrales P, Intaglietta M. Perfusion vs. 577 oxygen delivery in transfusion with "fresh" and "old" red 578 blood cells: the experimental evidence. Transfus Apheresis 579 Sci. 2010;43(1):69–78. 580
- Karafin MS, Francis RO. Impact of G6PD status on red cell storage and transfusion outcomes. Blood Transfus. 2019;17(4):289.
- Peters AL, van Bruggen R, de Korte D, Van Noorden CJ, Vlaar 583 AP. Glucose-6-phosphate dehydrogenase activity decreases 584 during storage of leukoreduced red blood cells. Transfusion 585 (Paris). 2016;56(2):427–32. 586
- Sutasir YT, Kazezoglu C, Komurcu SZM, Tabak O. Contribution 587 of laboratory clinical consultation for excessively low Hba1c 588 results to the diagnosis. Int J Med Biochem. 2020;3(3):189–91. 589